Research results will be presented at the upcoming Annual Meeting of the Japanese
Cancer Association regarding the analysis of the selective delivery mechanism of the drug
delivery technology "pullulan nanogel", which is the foundation of our company, to tumor-
associated macrophages and its application to cancer treatment drugs.

"Pullulan Nanogel Selectively Delivers Drugs to Tumor-Associated Macrophages by
Binding to Its Receptor, DC-SIGN (Search for target molecules of CHP nanogel as tumor-
associated macrophage-targeted DDS and Development of novel immunotherapy)"
Our presentation will be held at the poster presentation venue on Thursday, September 29.